Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
A new plant-based serum is claimed to regrow hair in weeks, but users are skeptical about its effectiveness and the reliability of the study. Ingredients like Centella Asiatica and IGF-1 are mentioned, but many doubt the serum's superiority over existing treatments like Minoxidil and finasteride.
Exosome hair therapy involves injecting stem cell-derived exosomes into the scalp to boost hair follicle regeneration and repair. Exosomes, which are not stem cells but products of them, contain bioactive chemicals and specific growth factors that promote new blood vessel formation, increase cell proliferation, reduce inflammation, and improve tissue repair, all crucial for hair health.
Regrowing hairline without the use of Minoxidil or Finasteride, and instead using mechanical stimulation such as Derma Roller, Nizoral, Zinc Pyrithione, Scalp Massage, Scalp Exercise, Fish Oil and other topical solutions. It is cautioned that there are risks associated with not using medically-prescribed treatments, but it is suggested to consider mechanical stimulation in addition to those prescribed treatments.
A young person regrets not starting hair loss treatments like minoxidil and finasteride earlier, leading to significant balding by age 19. They discuss the importance of early intervention and the impact of societal perceptions on those experiencing hair loss.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.
A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.
User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hair regeneration therapy, stem cell therapy, exosome therapy, and dermal exosomes provided.
The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
Finasteride and Propecia are essentially the same, but some people may respond differently due to inactive ingredients. If cost is not an issue, Propecia is preferred due to better quality control and consistent results.
Finasteride is helping regrow hair in previously thinning areas, and the user plans to add minoxidil to enhance results. The user is considering increasing the finasteride dose to 1mg daily for better outcomes.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.
The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.
Stem cell treatment research shows promise in reversing hair loss in mice, but it's likely 10 years away and expensive. Current recommended treatments include minoxidil, finasteride, and hair transplants.
PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.
The user is frustrated with the lack of visible hair regrowth after 7-8 months of using finasteride and minoxidil, despite initial vellus hair growth. Others suggest patience, switching to oral minoxidil, or using additional treatments like dermastamping, microneedling, and red light therapy.
Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.
The conversation is about experimenting with microneedling and growth factor topicals for hair growth, avoiding Minoxidil due to shedding concerns. The treatment includes microneedling, growth factor topicals, finasteride, biotin, and a caffeine shampoo.
A 28-year-old shared surprising hair regrowth progress after 20 days using topical minoxidil, micro needling, GHK-cu, and BPC-157 injections. The user noted a significant reduction in their bald spot and overall hair improvement.
The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Concerns about the impact of hair loss treatments like finasteride on fertility and future children. The user is worried about reduced sperm count and quality due to lowered DHT levels.
The user reports positive results using a multi-peptide serum for hair density, combined with finasteride and melatonin, after stopping minoxidil. They experienced hair regrowth after previously losing hair despite using finasteride and minoxidil.